Non Interventional (NI) Open Label Prospective Study On Liprimar (Atorvastatin) In Patients With Coronary Heart Disease (CHD) And High Risk Of Cardiovascular Complications.

Trial Profile

Non Interventional (NI) Open Label Prospective Study On Liprimar (Atorvastatin) In Patients With Coronary Heart Disease (CHD) And High Risk Of Cardiovascular Complications.

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Jan 2013

At a glance

  • Drugs Atorvastatin (Primary)
  • Indications Coronary artery disease; Hyperlipidaemia
  • Focus Therapeutic Use
  • Acronyms LIGHT
  • Sponsors Pfizer
  • Most Recent Events

    • 04 Jan 2012 Actual patient number is 758 according to ClinicalTrials.gov.
    • 04 Jan 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
    • 04 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top